files registration statement for listing of ad

ASX/Media Release 14/2/2012
PRIMA BIOMED FILES REGISTRATION STATEMENT FOR LISTING OF ADRs ON NASDAQ
Australian healthcare company Prima BioMed Ltd (ASX: PRR) (Prima) announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission to enable a listing on the NASDAQ Global Market (NASDAQ) of American Depositary Receipts (ADR).
Upon listing on the NASDAQ the Company will have dual listings of its securities on both the Australian Securities Exchange (ASX) and NASDAQ. Every one ADR will represent 30 common shares. Prima’s proposed NASDAQ listing will be a Level II ADR compliance listing, and is being managed by Bank of New York Mellon and US broking houses Deutsche Bank AG, Noble Financial and Aegis. The Company is unable at this time to comment on the expected timing of the listing.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
ENDS
About Prima BioMed
Prima BioMed is an ASX listed Australian health care company. The Company is focused on technologies in the fields of cancer immunotherapy.
For further information please contact:
Mr Martin Rogers James Moses
Chief Executive Officer Investor and Media Relations
Prima BioMed Mandate Corporate
Ph: +61 (2) 9276 1242 Ph: +61 (0) 420 991 574
E: [email protected] E: [email protected]
US Investor Relations
Ms Kathy Galante
Investor Relations
Burns McClellan, Inc
Ph: +1 (212) 213-0006
E: [email protected]